We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Gamida Cell Ltd | NASDAQ:GMDA | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.0327 | 0.0302 | 0.0304 | 0 | 01:00:00 |
From Jul 2022 to Jul 2024
By Josh Beckerman
Gamida Cell Ltd. shares rose 34% to $1.08 Monday after the U.S. Food and Drug Administration approved the Boston-based biotechnology company's Omisirge cell therapy for certain blood cancer patients.
Omisirge is a substantially modified allogeneic cord blood-based cell therapy aimed at quickening the recovery of neutrophils and reducing the risk of infection.
The cell therapy was approved by the FDA for patients 12 years and older with blood cancers who undergo umbilical cord blood transplantation following a myeloablative conditioning regimen.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
April 17, 2023 14:15 ET (18:15 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Gamida Cell Chart |
1 Month Gamida Cell Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
